

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

NCT05136976

Status	RECRUITING
Phase	Phase 3
Sponsor	Centre Hospitalier Universitaire de Saint Etienne
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (9)

- Disease duration of 5 years or less and documented clinical worsening (clinical or ENMG or disability) over the past 24 months
- IgM gammopathy, either MGUS or Waldenstrom Macroglobulinemia (WM)
- Demyelinating polyneuropathy according to European Federation of Neurological Societies/Peripheral Nerve Society guidelines for chronic inflammatory demyelinating polyneuropathy on nerve conduction studies.
- Anti-MAG titre of 10 000 BTU or more
- Total INCAT score of 1 point or more at baseline
- ... and 4 more (see full listing online)

Exclusion (19)

- \- Unable to give informed consent
- History of severe allergic or anaphylactic reaction to chimeric monoclonal antibody
- Hypersensitivity known to one of the compounds of polaramine or methylprednisolone
- Previous treatment with rituximab
- Diseases known to cause polyneuropathy (e.g. diabetes, uncontrolled thyroid disease, vitamin B1 or B12 deficiency, renal (GFR \lt 60ml ml/min/1,73 m²- Modification of Diet in Renal Disease (MDRD) formula) or liver disorder, myeloma, amyloidosis, cryoglobulinemia)
- ... and 14 more (see full listing online)

Locations (15 total)

CHU Brest - La cavale blanche, Brest, France
CHU Grenoble - La tronche, Grenoble, France
CHU Lille - Roger Salengro, Lille, France
... and 12 more locations